140 related articles for article (PubMed ID: 8366295)
1. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E
Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295
[TBL] [Abstract][Full Text] [Related]
2. Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring.
Molina R; Jo J; Filella X; Zanon G; Grau JJ; Joseph J; Bedini JL; Biete A; Ballesta AM
Int J Biol Markers; 1993; 8(2):113-23. PubMed ID: 8366294
[TBL] [Abstract][Full Text] [Related]
3. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
5. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer.
Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF
Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068
[TBL] [Abstract][Full Text] [Related]
6. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mucinous carcinoma associated antigen (MCA) levels in patients with breast cancer.
Migali E; Ozzola G; Mariotti D; Ghezzi P; Rinaldini M; Magnanini S
Int J Biol Markers; 1992; 7(1):61-4. PubMed ID: 1583350
[No Abstract] [Full Text] [Related]
8. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
9. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M
Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185
[No Abstract] [Full Text] [Related]
10. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the new tumor marker MCA in the follow-up of patients with mammary carcinoma.
Müller-Brand J; Mäcke H
Int J Biol Markers; 1993; 8(2):130-2. PubMed ID: 8366296
[TBL] [Abstract][Full Text] [Related]
13. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
Yenisey C; Güner G
Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
[No Abstract] [Full Text] [Related]
14. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
Gion M; Mione R; Gatti C; Dittadi R; Leon A; Nascimben O; Pizzorno B; Bruscagnin G
Tumori; 1990 Aug; 76(4):360-4. PubMed ID: 2399565
[TBL] [Abstract][Full Text] [Related]
15. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F
Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
18. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
Kopczyński Z; Thielemann A
Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
[TBL] [Abstract][Full Text] [Related]
19. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
20. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]